Page 3 - Plan Associates News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Australian biotechnology manufacturers are invited to contribute to global benchmarking, with the 19th Annual Biopharmaceutical Manufacturing global

Here are the top stocks to track in today's session: Dodla Dairy, KIMS: Two companies will list on the bourses on Monday, namely Dodla Dairy and Krishna Institute of Medical Sciences (KIMS). The two IPOs that ran between June 16-18 were subscribed 46 times and 4 times, respectively. Earnings Today: More than 300 companies are slated to post their quarterly numbers today including NALCO, Future Lifestyle, Zee Media, GIC Housing Finance and NLC India. IndiGo: Shareholders of InterGlobe Aviation, parent of airline IndiGo, have approved a proposal to raise up to Rs 3,000 crore. The funds would be...

Shares of Dodla Dairy will debut on the bourses today, 28 June 2021. Dodla Dairy offer closed for subscription on June 18 after being subscribed 45.62 times. Issue price is Rs 428 per share. Shares of Krishna Institute of Medical Sciences (KIMS) will debut on the bourses today, 28 June 2021. KIMS Hospitals public offer witnessed an oversubscription of 3.86 times during June 16-18. Issue price is Rs 825 per share. Reliance Industries (RIL) said that the Fluidized Catalytic Cracker Unit (FCCU) in SEZ refinery at Jamnagar which was taken for an emergency shutdown on June 6, 2021 has been restar...

Key benchmark indices are trading firm in early trade on buying demand in index pivotals. At 9:25 IST, the barometer index, the S&P BSE Sensex, was up 97.94 points or 0.19% at 53,022.98. The Nifty 50 index was up 26.75 points or 0.17% at 15,887.10. The Sensex regained the psychological 53,000 mark in opening trade. Asian stocks are trading mixed. The S&P BSE Mid-Cap index was up 0.3%. The S&P BSE Small-Cap index was up 0.6%. The market breadth, indicating the overall health of the market, is strong. On the BSE, 1774 shares rose and 856 shares fell. A total of 115 shares were unchanged. Stocks...

Cell & Gene Therapy Bioprocessing: Demand For Better Process Control, Expertise & CMOs By Ronald A. Rader and Eric S. Langer, BioPlan Associates, Inc. Manufacturing capacity for both cellular therapies and gene therapy viral vectors remains in short supply.  From our research, including interviews with developers, there is a current and worsening capacity crunch. BioPlan Associates, Inc. annually surveys biopharmaceutical manufacturing professionals and publishes data on capacity and other industry concerns. 1 The survey, now in its 18 th year, includes 147 end users’ responses and also pr...